Browse News
Filter News
Found 17,054 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
The two companies have settled all pending U.S. patent litigation, clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of Stelara.
-
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
11/30/2023
TFF Pharmaceuticals, Inc. today announced the appointment of Michael Patane, Ph.D., to its Board of Directors.
-
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
11/30/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category.
-
The Swiss pharma is adopting a more streamlined strategy focusing on core therapeutic areas: cardiovascular, immunology, neuroscience and oncology, as well as renal and metabolic diseases.
-
Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
11/29/2023
Agomab Therapeutics NV announced the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
-
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
-
Keep up with the regulator’s latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
11/28/2023
Erasca, Inc. announced program updates for pan-RAF inhibitor naporafenib and central nervous system -penetrant EGFR inhibitor ERAS-801, as well as a strategic program prioritization that extends its projected cash runway from H2 2025 to H1 2026.
-
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
11/28/2023
Pyxis Oncology, Inc. announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective November 27, 2023.
-
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
11/28/2023
Alvotech (NASDAQ: ALVO, or the “Company”) today reported unaudited financial results for the first nine months of 2023 and provided a summary of recent corporate highlights.
-
While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.
-
Study Finds Online Course Effectively Trains Health Workers to Detect Glaucoma
11/27/2023
New research shows that a short online course designed by global eye care nonprofit Orbis International successfully trains health care workers to identify signs of glaucoma at a level similar to local ophthalmologists.
-
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
11/27/2023
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc.
-
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
11/24/2023
Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing.
-
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
11/22/2023
Procaps Group announced a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group.
-
The biotech company has bought the global rights to an investigational oral CDK2 inhibitor from Ensem Therapeutics in a licensing agreement valued at up to $1.33 billion if all milestones are met.
-
Biosimilar Monoclonal Antibody Market Size to Surpass USD 69 Billion By 2032
11/21/2023
The global biosimilar monoclonal antibody market size was valued at USD 8.6 billion in 2022 and is projected to surpass around USD 69 billion by 2032, expanding at a healthy CAGR of 23.2% from 2023 to 2032.
-
Halia Therapeutics to Present at the 5th Inflammasome Therapeutics Summit
11/20/2023
Halia Therapeutics announced that David Bearss, Ph.D., President and Chief Executive Officer of Halia, will be participating in a panel discussion and presenting new data at the 5th Inflammasome Therapeutics Summit taking place on November 28 – 30, in Boston, MA.
-
Sickle Cell Disease Treatment Market Size to Garner Around USD 50.45 Billion by 2032
11/20/2023
The global sickle cell disease treatment market size is estimated to garner around USD 50.45 billion by 2032 and is expanding at a healthy CAGR of 35.1% from 2023 to 2032.